
    
      OBJECTIVES:

        -  Compare the efficacy of cevimeline vs placebo, in terms of dryness of the oral cavity
           and salivary flow, in patients with xerostomia secondary to radiotherapy for cancers in
           the head and neck region.

        -  Assess the safety of this drug in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral cevimeline 3 times daily for 12 weeks in the absence of
           unacceptable toxicity.

        -  Arm II: Patients receive oral placebo as in arm I.

      PROJECTED ACCRUAL: A total of 280 patients (140 per arm) will be accrued for this study.
    
  